Peter Rost, M.D., is a former Pfizer Marketing Vice President providing services as a medical device and drug expert witness and pharmaceutical marketing expert. Judge Sanders: "The court agrees with defendants' view that Dr. Rost is a very adept and seasoned expert witness." He is also the author of Emergency Surgery, The Whistleblower and Killer Drug. You can reach him on rostpeter (insert symbol) hotmail.com. Follow on https://twitter.com/peterrost
Any commentary yet on the Eli Lilly $1.42 billion settlement-- other than that it still falls far short of the $18.5 billion Lilly made for marketing the drug off-label (it was stated that 1/2 of the profits from the drug came from off-label prescriptions, and was separately stated that the profits over the period in question was $39 billion-- hence I calculate that to mean that they made $18.5 (so far) from marketing the drug (zyprexa) off-label.
In that context there were no double or triple damages, no fines on top of damages of $5,500 to $11,000 per violation, etc.
Indeed, there weren't even single damages, which would have required paying back $18.5 billion.
Instead, they were only made to pay $1.42 billion-- leaving this largest pharmaceutical fraud recovery to date still nothing more than a cost of doing business to the fraudster.
Hmmm. So it's going to cost me $1.42 billion but I'll make $18.5 billion??? What business school ever taught their students not to take THAT deal??? That's more than a 1300% straight profit (return on investment).
So, will this fraud continue by Lilly and all other drug companies under both a return on investment model and an aggression dynamic paradigm? You can bet your sweet biffy that it will!!!
Prosecutors just don't understand what it means to get tough on crime!!!
1 comment:
Any commentary yet on the Eli Lilly $1.42 billion settlement-- other than that it still falls far short of the $18.5 billion Lilly made for marketing the drug off-label (it was stated that 1/2 of the profits from the drug came from off-label prescriptions, and was separately stated that the profits over the period in question was $39 billion-- hence I calculate that to mean that they made $18.5 (so far) from marketing the drug (zyprexa) off-label.
In that context there were no double or triple damages, no fines on top of damages of $5,500 to $11,000 per violation, etc.
Indeed, there weren't even single damages, which would have required paying back $18.5 billion.
Instead, they were only made to pay $1.42 billion-- leaving this largest pharmaceutical fraud recovery to date still nothing more than a cost of doing business to the fraudster.
Hmmm. So it's going to cost me $1.42 billion but I'll make $18.5 billion??? What business school ever taught their students not to take THAT deal??? That's more than a 1300% straight profit (return on investment).
So, will this fraud continue by Lilly and all other drug companies under both a return on investment model and an aggression dynamic paradigm? You can bet your sweet biffy that it will!!!
Prosecutors just don't understand what it means to get tough on crime!!!
Post a Comment